Objectives: To assess the prevalence of efflux and amino acid substitutions in ParC and GyrA in Canadian clinical isolates of fluoroquinolone-susceptible Streptococcus pneumoniae with levofloxacin MICs of 1 mg/L collected before the introduction of the respiratory fluoroquinolones (1995)(1996)(1997) and after 7 years of use (2003).
Introduction
The introduction of respiratory fluoroquinolones such as levofloxacin to the Canadian market in 1997 was an important advance in treatment of respiratory infections caused by Streptococcus pneumoniae, the leading cause of community-acquired pneumonia. 1 The development of the first respiratory fluoroquinolone led to the development of a series of potent anti-pneumococcal agents such as moxifloxacin, gatifloxacin and gemifloxacin. 1 The fluoroquinolones act in S. pneumoniae by targeting the type II topoisomerases: topoisomerase IV and DNA gyrase. [2] [3] [4] [5] [6] Resistance to fluoroquinolones arises by stepwise accumulation of spontaneous point mutations in the quinolone-resistance determining regions (QRDR) of these target enzymes that result in decreased binding affinity of the drug. 5, 7, 8 Topoisomerase IV is composed of two ParC subunits and two ParE subunits. Likewise, DNA gyrase is composed of two GyrA subunits and two GyrB subunits. A primary mutation in parC resulting in an amino acid substitution leads to low-level fluoroquinolone resistance (ciprofloxacin MICs of 4 or 8 mg/L). Upon acquisition of this first mutation, secondary mutations in gyrA may develop resulting in high-level resistance (ciprofloxacin MICs of ‡16 mg/L). 2, [5] [6] [7] [8] These secondary gyrA mutations have been shown to arise at a significantly higher rate than the primary parC mutations. 7 Resistance may also be attributed to efflux and mutations in parE and gyrB. 5 Fluoroquinolone efflux in S. pneumoniae is thought to be mediated by a reserpine-sensitive pump driven by the proton motive force. Despite the low level of fluoroquinolone resistance in Canada, cases of respiratory fluoroquinolone treatment failure due to isolates possessing first-step parC mutations have been documented. 7, 10 Although the number of treatment failures is small compared with the hundreds of millions of patients treated with these agents, these failures have emphasized that current susceptibility testing methods are often unable to identify isolates with first-step mutations. 7, 10 The major concern is that the use of the respiratory fluoroquinolones will create a pool of susceptible isolates that contain unidentified first-step mutations (e.g. parC) and these isolates will readily acquire a second mutation upon treatment with a fluoroquinolone resulting in high-level fluoroquinolone resistance. 3, 7 Since most research to date has focused on the prevalence of parC mutations in clinical isolates with a levofloxacin MIC of 2 mg/L and reports agree that mutations in these isolates are very common, 3, 7, 8 we focused on clinical isolates with a levofloxacin MIC of 1 mg/L. To assess whether the introduction of respiratory fluoroquinolones has had an impact on fluoroquinolone-susceptible isolates in Canada, we set out to determine the prevalence of resistance-associated mechanisms, including mutations in the QRDRs of parC and gyrA, as well as efflux, among 776 fluoroquinolone-susceptible S. pneumoniae isolates
This study compares the prevalence of these mechanisms among Canadian respiratory isolates collected before the introduction of any respiratory fluoroquinolone in Canada (1995) (1996) (1997) 
Materials and methods

Bacterial strains and susceptibility tests
All S. pneumoniae clinical isolates investigated in this study were collected as part of an ongoing national respiratory organism surveillance programme (CROSS: Canadian Respiratory Organism Susceptibility Study). 11 The isolates were obtained from 25 medical centres in nine of the 10 Canadian provinces. Isolates were identified using conventional methodology and were considered to be significant respiratory pathogens based on each laboratory's existing protocol. MICs were determined using the National Committee for Clinical Laboratory Standards (NCCLS) microbroth dilution technique after the isolates were sub-cultured twice from frozen stock.
12 Broth microtitre plates were made in-house with antimicrobials obtained as laboratory grade powders from their respective manufacturers, stock solutions prepared, and dilutions made as described by NCCLS.
12 Antimicrobials tested included ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin. The broth microtitre plates were inoculated with a final bacterial concentration of 5 · 10 5 cfu/mL in Mueller-Hinton broth supplemented with 3-5% lysed horse blood and incubated for 22-24 h at 35 C in ambient air.
Mutation analysis
Sequencing of the QRDRs of parC and gyrA was performed for all isolates. Primers previously described by Morrissey and George 4 were used to generate PCR products of the QRDRs of gyrA and parC, which were then sequenced in the forward and reverse directions. An ABI PRISM Big Dye Terminator kit and ABI PRISM 3100 Genetic Analyzer (PE Applied Biosystems, Mississauga, Ontario, Canada) were used to conduct the sequencing.
Efflux determination
The prevalence of efflux was determined using a random sample consisting of 100 isolates from 1995 to 1997 and 300 isolates from 2003. The presence of efflux was assessed by ciprofloxacin agar dilution MICs on Mueller-Hinton agar plates supplemented with 5% sheep blood in the presence and absence of reserpine (10 mg/L). 2 Isolates for which the ciprofloxacin MIC was reduced fourfold or greater in the presence of reserpine were considered positive for reserpine-sensitive efflux. 2 Table 1 Table 1. Table 2 outlines the change in prevalence of amino acid substitutions that have been proven to be directly associated with fluoroquinolone resistance, including known resistance-associated substitutions in ParC and GyrA, as well as efflux. 2, 5 None of the clinical isolates exhibited greater than a twofold decrease in MIC in the presence of reserpine, and were therefore all considered negative for efflux. The percentage of fluoroquinolone-susceptible clinical isolates with a levofloxacin MIC of 1 mg/L that possessed known resistance-associated substitutions was 0.9% between 1995 and 1997, and 2.1% in 2003. Using the one-tailed Fisher's Exact Test, this is not a significant increase (P = 0.34). These data do not support the claim that the introduction of respiratory fluoroquinolones in Canada has resulted in an increase in first-step mutations among fluoroquinolone-susceptible isolates of S. pneumoniae.
Results and conclusions
Levofloxacin susceptibility is commonly used as a marker to predict susceptibility to other respiratory fluoroquinolones. 2 Current Clinical Laboratory Standards Institute susceptibility criteria deem isolates with a levofloxacin MIC ‡ 4 mg/L to be nonsusceptible. 13 However, it has been well documented that the majority of clinical isolates with a levofloxacin MIC of 2 mg/L possess a first-step parC mutation. 3, 8, 14 Since several reports document first-step mutations in clinical isolates with a levofloxacin MIC of 2 mg/L to range from 59% to 71%, 3, 14 redefining levofloxacin susceptibility criteria to include isolates having a levofloxacin MIC of no more than 1 mg/L has been suggested. 8 This same rationale has been proposed for reducing breakpoints of all fluoroquinolones for S. pneumoniae. The suggested resistant breakpoints based on genetics are as follows: gatifloxacin > 0.25 mg/L, moxifloxacin > 0.12 mg/L, gemifloxacin > 0.03 mg/L. 8 Reductions in the breakpoints for all fluoroquinolones versus S. pneumoniae may reduce the probability of treatment failure that is due to the presence of unidentified first-step mutations. 8, 14 Treatment failures may be averted by reducing the breakpoints to a levofloxacin MIC of 1 mg/L where, as we have confirmed, the likelihood of finding isolates with first-step mutations is currently low.
In further investigations, our isolates were divided into groups based on ciprofloxacin MIC to assess whether a trend was evolving amongst isolates with a ciprofloxacin MIC of 2 mg/L and a levofloxacin MIC of 1 mg/L in comparison with isolates with a ciprofloxacin MIC of 1 mg/L and a levofloxacin MIC of 1 mg/L. The percentage of isolates harbouring resistance-associated mutations from the cohort with a ciprofloxacin MIC of 2 mg/L increased from 2.6% (1995-1997) to 10.8% (2003) over the 7 year period (P = 0.12). Additionally, we observed a significant increase over time in the prevalence of isolates that had a ciprofloxacin MIC of 2 mg/L and a levofloxacin MIC of 1 mg/L from 3.9% to 6.5% (P = 0.0021). Although the overall prevalence of mutations among clinical isolates with a levofloxacin MIC of 1 mg/L remains stable, these data suggest that fluoroquinolones appear to be selecting for isolates with elevated ciprofloxacin MICs. A trend towards increased prevalence of mutations among isolates with a ciprofloxacin MIC of 2 mg/L and a levofloxacin MIC of 1 mg/L is probably emerging. This would suggest that there are discrepancies based on ciprofloxacin MIC, and predicting the presence of first-step mutations, and thus the possibility of treatment failure due to emergence of resistance, should be based on the combined ciprofloxacin and levofloxacin MICs as opposed to using a single marker such as levofloxacin alone.
A recent review by Fuller and Low 10 suggests that patient risk factors may also aid in identifying infections that have a high risk of fluoroquinolone treatment failure. Such factors include residence in a long-term care facility, hospitalization and a history of fluoroquinolone use.
Recent clinical failures have highlighted the difficulty in detecting first-step mutations with the phenotypic method based on MICs using current levofloxacin breakpoints. 7, 10 Reducing fluoroquinolone breakpoints, using ciprofloxacin MIC as well as levofloxacin MIC, and identifying patient risk factors may all act to reduce the risk of fluoroquinolone clinical failure due to first-step mutations in S. pneumoniae. 
